Agenus | AGEN - Betriebsergebnis

Aktienkurs
4.68
Täglich Wechseln
-0.04 -0.85%
Monatlich
42.25%
Jährlich
183.64%
Q2 Prognose
3.85




Betriebsergebnis Veränderung Datum
AbbVie USD 5.81B 1.23B 2025-12
Agenus USD 14.4M 19.26M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Celldex Therapeutics USD -87.15M 13.54M 2025-12
CSL USD 2.64B 1.97B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 383.88M 47.43M 2025-12
Intrexon USD -60.84M 26.62M 2024-06
J&J USD 6.62B 1.03B 2026-03
Jiangsu Hengrui CNY 2.25B 848.02M 2025-12
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
Merck EUR 474M 738M 2025-12
Merck USD 6.24B 318M 2025-12
Northwest Biotherapeutics USD -14.32M 481K 2025-09
Novartis USD 4.06B 437M 2025-12
Novavax USD 20.94M 100.32M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Veracyte USD 24.63M 1.52M 2025-12